Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

By Watson D.J.   Bolognese J.A.   Yu C.   Krupa D.   Curtis S.  

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 1899-1908

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular effects of cyclooxygenase‐2 inhibitors: a mechanistic and clinical perspective

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 82, Iss. 4, 2016-10 ,pp. : 957-964

John Wiley & Sons Inc

Access to resources Recommend Favorite

Enhancement of the Sensitivity of Renal Cell Carcinoma Cells to Fas-Mediated Cytotoxicity and Apoptosis by the Selective Cyclooxygenase-2 Inhibitor JTE-522

By  

Urologia Internationalis, Vol. 84, Iss. 3, 2010-04 ,pp. : 362-368

Karger

Access to resources Recommend Favorite

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib

By Curtis Sean P.   Ko Amy T.   Bolognese James A.   Cavanaugh Paul F.   Reicin Alise S.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2365-2374

Informa Healthcare

Access to resources Recommend Favorite

The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II

By Knudsen James   Carlsson Uno   Hammarström Per   Sokol Gerald   Cantilena Louis  

Inflammation, Vol. 28, Iss. 5, 2004-10 ,pp. : 285-290

Springer Publishing Company

Access to resources Recommend Favorite